Literature DB >> 9012279

Contemporary medical therapy for gastroesophageal reflux disease.

R Fass1, L J Hixson, M L Ciccolo, P Gordon, G Hunter, W Rappaport.   

Abstract

Gastroesophageal reflux disease is a chronic disorder that requires long-term therapy in most patients. The appropriate medical therapy should be individualized to the severity of symptoms, the degree of esophagitis and the presence of other acid-reflux complications. Lifestyle changes should form the basis of any therapeutic approach. In patients with mild to moderate disease, initial therapy with histamine H2-receptor antagonists in conventional dosages is suggested. Prokinetic agents are potentially useful in patients with impaired esophageal or gastric motor function, but their efficacy as single agents does not appear to surpass that of standard doses of H2 blockers. Sucralfate, a cytoprotective agent, is an additional therapeutic option. For patients with more severe disease, omeprazole and lansoprazole provide unequaled healing rates and accelerated symptom relief. In most patients, maintenance therapy is vital. Surgery is indicated in patients whose disease is refractory to medical therapy and in those who develop complications not amenable to medical therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9012279

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  5 in total

1.  Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD).

Authors:  Craig W Hayden; Charles N Bernstein; Renée A Hall; Nimish Vakil; Harinder S Garewal; Ronnie Fass
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 3.  Switching between intravenous and oral pantoprazole.

Authors:  J R Pisegna
Journal:  J Clin Gastroenterol       Date:  2001-01       Impact factor: 3.062

Review 4.  Refractory gastroesophageal reflux disease.

Authors:  Charumathi Raghu Subramanian; George Triadafilopoulos
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-09-30

Review 5.  New and future drug development for gastroesophageal reflux disease.

Authors:  Carla Maradey-Romero; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2013-12-30       Impact factor: 4.924

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.